Pharmacogenomic testing, a mature and growing aspect of personalized medicine, has demonstrated significant ability to enhance health outcomes and reduce healthcare costs. Since the 1970s, pharmacogenomics has continued to validate substantial effectiveness in optimizing clinical care. While current government and commercial efforts to negotiate competitive drug prices are important, this focus represents a minor—and misplaced—implementation of medication management. It’s time that policymakers, insurers and healthcare providers make pharmacogenomic testing a fundamental standard of care delivery.
Several reasons highlight the importance of pharmacogenomic testing:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
First, pharmacogenomic testing can help streamline medication selection and dosing, leading to more effective and personalized treatment plans. For example, research has shown that at least 30% of medications prescribed are ineffective, unsafe, or both for certain patients. By identifying an individual’s genetic makeup and how it affects their response to drugs, healthcare providers can tailor medication choices and doses to optimize efficacy while minimizing adverse reactions. This precision medicine approach can reduce the need for trial-and-error prescribing, which often leads to wasted time and resources on ineffective treatments, increased healthcare visits, and the potential for adverse drug reactions. Ultimately, this targeted approach can improve patient outcomes and satisfaction while reducing the economic burden of medical appointments and hospitalizations due to medication failure.
Secondly, implementing pharmacogenomic testing can enhance the safety of drug therapy, which has a direct impact on healthcare costs. Adverse drug reactions are a major driver of healthcare expenses, leading to hospitalizations, additional treatments, and prolonged hospital stays. A recent CDC study revealed that 1.3 million emergency room visits alone are caused by adverse drug reactions each year. Pharmacogenomic testing can help identify patients at a higher risk for adverse reactions, allowing for the adjustment of medication choices or doses to mitigate these risks. By reducing the incidence of adverse drug reactions, healthcare costs associated with hospitalization and emergency care can be significantly reduced, leading to cost savings for both patients and healthcare systems.
Lastly, the broader implementation of pharmacogenomic testing can contribute to a more efficient and cost-effective healthcare system. As genetic testing technology advances and becomes more accessible, incorporating pharmacogenomics into routine clinical practice can result in a more data-driven approach to medication management. This data-driven approach can lead to the development of treatment guidelines and policies that are based on solid genetic evidence, reducing variability in care and enhancing treatment consistency. Researchers estimate that approximately 16% of total U.S. healthcare costs—$674 billion per year—can be eliminated by avoiding medication failure. Furthermore, pharmacogenomics can lead to better-informed decisions on medication pricing, focusing on the value of effective treatments, which can ultimately influence healthcare costs in a positive manner.
By addressing the lethargy of the status quo, pharmacogenomic testing offers a promising avenue for improving health outcomes and controlling healthcare costs. This approach provides personalized, data-driven treatment options, enhances medication safety, and contributes to a more efficient healthcare system. As the field of pharmacogenomics continues to evolve and become more accessible, it has the potential to revolutionize how healthcare is delivered, ultimately benefiting patients and the healthcare system as a whole.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo: Andrew Brookes, Getty Images
Jim Wallace comes from a career in health care, as head of strategy for Anthem, president of AmeriPlus, and chief executive officer of DecisionRx, the pioneering medication therapy optimization company. Prior to his career in health care, Jim was a combat pilot in the U.S. Army and a strategy consultant with Bain & Company. Jim has also worked with the Walt Disney Company, Fox Entertainment, and SpaceX, leading domestic and international business development efforts as senior advisor to the board and CEO.
Jim has a Bachelor of Science degree from the U.S. Military Academy, a Master of Business Administration degree from Harvard Business School, and a Doctor of Business Administration degree from the University of South Florida. Jim’s strategy, capital markets, and business development experience combine with his 30 years of corporate and government relationships to bring a unique combination of knowledge and discipline to organizations he works with.
